Twist Bioscience's Q1 2025 Earnings: A Beacon of Growth in Synthetic Biology

Twist Bioscience Corp. (TWST), a leading player in the synthetic biology and genomics space, recently reported its first quarter fiscal 2025 earnings, providing investors with a glimpse into the company's strong financial performance and growth prospects. The South San Francisco-based company reported a loss of $31.6 million, or 53 cents per share, for the quarter, surpassing Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 62 cents per share. Twist Bioscience's revenue of $88.7 million also exceeded Street forecasts, with four analysts surveyed by Zacks expecting $86.9 million.